Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EPS (Weighted Average and Diluted) (2020 - 2025)

Fate Therapeutics (FATE) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.27 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 40.0% year-over-year to -$0.27, compared with a TTM value of -$1.15 through Dec 2025, up 30.3%, and an annual FY2025 reading of -$1.15, up 29.88% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.27 for Q4 2025 at Fate Therapeutics, roughly flat from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.19 in Q1 2023 and bottomed at -$0.86 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.47, with a median of -$0.45 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 72.06% in 2023, then plummeted 147.37% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.72 in 2021, then increased by 19.44% to -$0.58 in 2022, then rose by 22.41% to -$0.45 in 2023, then changed by 0.0% to -$0.45 in 2024, then skyrocketed by 40.0% to -$0.27 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for FATE at -$0.27 in Q4 2025, -$0.27 in Q3 2025, and -$0.29 in Q2 2025.